Age-related Conditions in the Context of Multimorbidity and Frailty: Relative Weight of Frailty in Determining the Course and Outcomes of Different Chronic Diseases and Viceversa

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06324149

Acronym

AGE-IT-FRAILTY

Enrollment

500

Registered

2024-03-21

Start date

2024-03-07

Completion date

2026-04-30

Last updated

2025-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frailty, Sarcopenia

Brief summary

Observational study. Participants of the FRASNET study (9th March 2017, Protocol No. 24/INT/2017) who were evaluated in 2016 and 2017 will be contacted to be re-evaluated with multidimensional visits as part of the present study in order to assess trajectories and biomarkers of frailty and sarcopenia. Moreover, are going to evaluate with the same multidimensional visits patients with mild cognitive impairment and dementia followed up at the Neurologic Unit of the San Raffaele Hospital.

Interventions

DIAGNOSTIC_TESTcompletion of scales and questionnaires; venous blood sampling; muscle ultrasound; cardiac ultrasound; electrocardiogram; bioelectrical impedance analysis

The sub-investigator performs a multidimentional geriatric evaluation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Inclusion criteria

* Having participated in the FRASNET study or being a patient with mild cognitive impairment or dementia followed up at the Neurologic Unit of the San Raffaele Hospital * Ability to sign written informed consent * \> 18 years old

Exclusion criteria

* Life expectancy \< 6 months * Unwillingness to participate in the study * Unstable clinical disease(for ex. serious acute pathologies)

Design outcomes

Primary

Measure	Time frame	Description
identify new molecular markers of frailty and sarcopenia	febbrary 2026	To identify new molecular markers of frailty and sarcopenia in elderly volunteers and patients suffering from mild cognitive impairment and dementia assay of biomarkers (HMGB1, sRAGE, FGF21, GFD15 and neurofilaments)

Secondary

Measure	Time frame	Description
evaluate the ability of new markers for frailty, sarcopenia, cognitive impairment	april 2026	To evaluate the ability of new markers (identified through the analysis of biobanked blood samples) to predict individual trajectories of frailty, sarcopenia, cognitive impairment and clinical outcomes assay of biomarkers (HMGB1, sRAGE, FGF21, GFD15 and neurofilaments)

Countries

Italy

Contacts

Primary ContactPatrizia Rovere Querini, PhD, MD

rovere.patrizia@hsr.it+390226433065

Backup ContactSarah Damanti, PhD, MD

damanti.sarah@hsr.it+390226433065

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026